Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL30674236 | 1.00 | GRIN1 (0.34) | GRIN1GRIN2BSLC6A2SLC6A3SLC6A4 | |
| Trifluoroacetic Acid SCHEMBL352869 | 1.00 | GRIN1 (0.34) | GRIN1GRIN2BSLC6A2SLC6A3SLC6A4 | |
| Oxalic Acid SCHEMBL352319 | 0.86 | SLC6A2 (0.36) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| Oxalic Acid SCHEMBL351294 | 0.86 | SLC6A2 (0.36) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL554471 | 0.84 | — | — | |
| SCHEMBL17137 | 0.84 | — | — | |
| SCHEMBL619548 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL15573075 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL352613 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL16333974 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120016120-A1 | PROCESS FOR PRODUCING 2-HYDROXYMETHYLMORPHOLINE SALT | DAISO CO., LTD. (JP) | 2012-01-19 | — | — | US | claimed |
| CN-115724847-A | 2, 3-dihydroimidazo [1,2-c ] quinazoline substituted derivatives | 拜耳知识产权有限责任公司 | 2023-03-03 | — | — | CN | disclosed |
| CN-101631464-B | 2,3-dihydroimidazo [1,2-c ] quinazoline substituted derivatives for the treatment of hyperproliferative diseases and angiogenesis-related diseases | 拜耳知识产权有限责任公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-108774232-B | 2, 3-dihydroimidazo [1,2-c ] quinazoline substituted derivatives | 拜耳知识产权有限责任公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-105254634-B | 2, 3-dihydroimidazo [1,2-c ] quinazoline substituted derivatives useful in the treatment of hyperproliferative diseases and angiogenesis-related diseases | 拜耳知识产权有限责任公司 | 2022-05-27 | — | — | CN | disclosed |
| US-RE46856-E1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-05-22 | — | — | US | disclosed |
| EP-2096919-B1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER IP GMBH (DE) | 2016-03-02 | — | — | EP | disclosed |
| US-8648190-B2 | Process for producing 2-hydroxymethylmorpholine salt | DAISO CO., LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-20130261113-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORPORATION | 2013-10-03 | — | — | US | disclosed |
| EP-2388252-B1 | PROCESS FOR PRODUCING 2-HYDROXYMETHYLMORPHOLINE SALT | DAISO CO LTD (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-8466283-B2 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-20120016120-A1 | PROCESS FOR PRODUCING 2-HYDROXYMETHYLMORPHOLINE SALT | DAISO CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
| EP-2388252-A1 | PROCESS FOR PRODUCING 2-HYDROXYMETHYLMORPHOLINE SALT | Daiso Co., Ltd. (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-8040010-B2 | Permanent magnet type generator and hybrid vehicle using the same | HITACHI, LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20110083984-A1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-14 | — | — | US | disclosed |
| EP-2096919-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008070150-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261113-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | PIK3CA, PIK3CD, PIK3CB | GRIN1 2333/4885GRIN2B 3282/4885SLC6A2 3678/4885 |
| US-20120016120-A1 | PROCESS FOR PRODUCING 2-HYDROXYMETHYLMORPHOLINE SALT | THOP1, AVPR2, HPD | GRIN1 672/4885GRIN2B 792/4885SLC6A2 77/4885 |
| US-20110083984-A1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | PIK3CA, PIK3CD, PIK3CB | GRIN1 2333/4885GRIN2B 3282/4885SLC6A2 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.